Thymosin Alpha-1 | Loti Labs

Premium USA-Made Research Compounds

Browse lab-tested peptides, research liquids, capsules and more.

Table of Contents

Thymosin Alpha-1: Immune Peptide Research, Mechanisms & Preclinical Findings

For laboratory and research use only. Not for human consumption.

35+ countries have approved it. The FDA gave it orphan drug status for four separate indications. It’s been studied continuously since 1977. And most Western researchers couldn’t pick it out of a lineup.

Thymosin Alpha-1 — Tα1. 28 amino acids from the thymus gland. It fires up TLR2 and TLR9 simultaneously, matures dendritic cells, pushes T-cell differentiation, and supercharges NK cell killing. The synthetic version goes by thymalfasin (brand name Zadaxin), and it’s been deployed against hepatitis B and C across Asia for years. In America? Investigational. Go figure.

Looking for Premium Research Compounds?

🧪 Peptides 💧 Research Liquids 💊 Capsules 🛒 Full Catalog

Chemical Identity

Twenty-eight residues. Acetylated serine at the N-terminus. Derived from prothymosin alpha — a larger 109-amino acid precursor that thymic epithelial cells chop up and release into circulation.

Sequence: Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN
Molecular Formula: C₁₂₉H₂₁₅N₃₃O₅₅
Molecular Weight: 3,108.3 g/mol
CAS: 62304-98-7

Heavily acidic — loaded with aspartate and glutamate residues. Net negative charge at physiological pH. That charge profile shapes how it binds receptors and separates it structurally from the other famous thymosin: thymosin beta-4 (TB-500), which weighs in at 4,921 g/mol and does tissue repair instead of immune modulation. Same family name. Entirely different biology.

Discovery Story

1960s. Allan Goldstein and Abraham White at Albert Einstein College of Medicine. They’re studying why the thymus gland matters for immune development. From calf thymus tissue they isolate “thymosin fraction 5” — a crude peptide soup that enhances immune function in animal models (Goldstein, 2007; Ann N Y Acad Sci 1112:1-13).

Ten years of purification work later, 1977: they pull out one specific 28-amino acid peptide from that fraction. Thymosin alpha-1. First individual peptide isolated from the thymic mixture that kept its immunological punch. The sequence got mapped. Production in rat thymus was confirmed (Hannappel & Huff, 1984; Proc Natl Acad Sci USA 81:1008-1011).

SciClone Pharmaceuticals later synthesized it as thymalfasin (Zadaxin) — identical amino acid sequence to the natural peptide. That synthetic version became the basis for regulatory filings across 35+ countries. From crude thymic extract to a defined, synthesized compound with international approvals. Took about three decades.

Mechanism of Action

Not a one-trick peptide. Tα1 orchestrates immune responses across innate and adaptive systems at the same time. Multiple receptor targets. Multiple cell types.

TLR2 + TLR9: Both At Once

Most immune compounds hit one receptor. Tα1 hits two Toll-like receptors on myeloid and dendritic cells.

Through TLR9: MyD88 cascade fires. IRF-7 gets activated. Cells pump out IFN-α — type I interferon. First-line antiviral defense. Through TLR2: NF-κB translocates to the nucleus. Now you’re getting IL-12, TNF-α, IL-6. Phagocytes wake up. Microbial recognition gets cranked.

The two arms amplify each other. TLR9’s IFN-α boosts the scale of TLR2-driven responses. Coordinated, not additive (Romani et al., 2006; Blood 108(7):2265-2274).

Dendritic Cells: From Immature to Armed

Tα1 matures dendritic cells. MHC class I and II go up. Co-stimulatory molecules (CD80/CD86) come online. Antigen processing capacity ramps.

But it’s not just activation. Tα1 also flips on IDO — indoleamine 2,3-dioxygenase — in DCs. That’s tryptophan catabolism. Creates a regulatory environment. Inflammation gets balanced against tolerance (Romani et al., 2006). Gas pedal and brake at the same time.

T Cells: The Core Function

Classic Tα1 territory. Thymic progenitors → functional CD4+ helpers and CD8+ killers. The two pillars of cellular immunity. But there’s more:

Tilts Th1/Th2 toward Th1 — cell-mediated over antibody-driven. Th17 and Treg populations also shift
Immunocompromised animals: T-cell counts partially restored. Function recovers. Rosette percentages climb
Boosts T-cell-dependent antibody production — hence the vaccine adjuvant research

NK Cells

Innate immune system’s hit squad. Tα1 activates their killing capacity directly — activating receptors get upregulated, IFN-γ production spikes, and there’s synergy with IL-2 for proliferation.

Different immunomodulatory angle: KPV peptide works through alpha-MSH receptors instead.

Cytokine Profile

Tα1’s signature: it boosts protective immune cytokines while damping inflammatory damage. That dual action is what makes it an immunomodulator rather than just an immune stimulant.

Cytokine	Direction	How	What It Means
IFN-α	↑	TLR9 → IRF-7	Antiviral innate response
IFN-γ	↑	NK and T-cell activation	Cellular immunity, macrophage priming
IL-2	↑	T-cell cascade	T-cell proliferation
IL-10	↑	Treg and DC modulation	Anti-inflammatory balance
IL-12	↑	TLR2 → NF-κB	Th1 polarization, NK boost
IL-1β	↓	Inflammasome regulation	Less inflammatory tissue damage
TNF-α	↓	Anti-inflammatory modulation	Controlled immune response

Protective cytokines go up. Damage cytokines come down. IL-10 — tolerance — also rises. It’s an unusually balanced profile. Most immune compounds tilt one direction. Tα1 manages to push immunity harder while simultaneously putting a leash on inflammatory damage. That’s rare.

Zadaxin: The Regulatory Story

SciClone Pharmaceuticals turned Tα1 into thymalfasin, sold as Zadaxin — a 1.6 mg subcutaneous injection. Here’s where it stands:

Approved in 35+ countries for hepatitis B/C research and immune enhancement
FDA orphan drug designation for: malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma
Phase II completed for hep B, Phase III for hep C in the US
Not approved in the US (beyond orphan designation), Japan, or most of Europe. Italy is the notable exception

Regulatory status varies enormously by country. In the US and EU, Tα1 remains investigational.

Preclinical Data

Hepatitis B

Enhanced viral clearance markers. Improved T-cell responses to HBV antigens. Modulated hepatic inflammation. Multiple research groups have examined thymalfasin in HBV models — Chien et al. (1998), Mutchnick et al. (1999), Zavaglia et al. (2000) — with varying designs and endpoint measurements.

Fungal Infections

TLR2 is a primary receptor for fungal cell wall components. That makes Tα1’s TLR2 agonism directly relevant. In immunocompromised animal models: improved fungal clearance and survival.

Immunodeficiency Recovery

Chemotherapy tanks the immune system. Tα1 in these models: accelerated immune recovery, increased T-cell counts, improved functional markers. It’s been studied as an adjunctive agent during immunosuppressive treatment.

Oxidative Stress

Beyond immune effects: Tα1 protected against oxidative damage by boosting liver SOD and glutathione peroxidase activity (Armutcu et al.). Cytoprotection on top of immune modulation.

Not TB-500. Don’t Confuse Them.

“Thymosin” is in both names. That’s where the overlap stops.

Tα1: 28 amino acids, 3,108 g/mol. Immune modulation — TLRs, dendritic cells, T cells, NK cells. Research focus: infection models, immune recovery.

TB-500 (thymosin beta-4): 43 amino acids, 4,921 g/mol. Tissue repair — actin dynamics, cell migration, angiogenesis. Research focus: wound healing, cardiac remodeling.

Same family. Completely different biology. TB-500 deep dive: thymosin beta-4 tissue regeneration guide.

Safety Profile

Favorable across preclinical studies. Key points:

Minimal adverse findings at standard research concentrations in animal models
Thymalfasin studied at 1.6 mg subcutaneous in investigational protocols
Anti-apoptotic: Tα1 antagonizes dexamethasone-induced thymocyte death in a time- and dose-dependent manner (Baumann et al., 2000; Int J Immunopharmacol 22(12):1057-1066)
Standard peptide storage requirements — temperature and handling matter for bioactivity

Where It Stands Legally

Approved in Asia and parts of Europe. FDA orphan designation but no US approval. Investigational in Japan and most Western countries except Italy. For research use — verify your jurisdiction’s rules.

Research Availability

From Loti Labs:

Thymosin Alpha-1 10mg — $79.99
LL-37 5mg — $94.99 (cathelicidin antimicrobial peptide — innate immune defense, distinct mechanism)

Also relevant: KPV peptide for alpha-MSH-mediated anti-inflammatory research.

Conclusion

Forty-plus years of data. Approvals on three continents. A mechanism that simultaneously strengthens protective immunity and controls inflammatory damage — TLR2 and TLR9 engagement, dendritic cell maturation, T-cell differentiation, NK activation, and a cytokine profile that goes up where it should and down where it should.

The open research fronts: DC biology and immune tolerance characterization, synergy with other immunomodulators, and immune recovery in post-immunosuppressive settings. For a peptide that’s been studied since 1977 and is still generating new mechanistic insights, Tα1 has staying power that most research compounds don’t.